Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2024 in Advanced Solid Tumors
NCT07539285Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HDM2024 in solid tumor, sponsored by Huadong Medicine. Primary endpoints: Maximal Tolerance Dose at 21 days, Recommended Phase 2 Dose at 1 year and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
HDM2024
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07539285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539285.